Date: Apr 07, 2014 Author: Caroline Copley Source: Reuters (
click here to go to the source)
Swiss drugmaker Roche has agreed to buy privately-held U.S. diagnostics company IQuum in a deal worth up to $450 million to strengthen its molecular diagnostics business.
The Basel-based firm said it will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.
"With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point of care segment," said Roland Diggelmann, head of Roche's diagnostics division, in a statement on Monday.
